Rhumbline Advisers Dynavax Technologies Corp Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Rhumbline Advisers holds 292,121 shares of DVAX stock, worth $3.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
292,121
Previous 310,805 6.01%
Holding current value
$3.76 Million
Previous $3.49 Million 6.76%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$10.05 - $11.61 $187,774 - $216,921
-18,684 Reduced 6.01%
292,121 $3.25 Million
Q2 2024

Aug 01, 2024
BUY
$10.73 - $12.58 $57,716 - $67,667
5,379 Added 1.76%
310,805 $3.49 Million
Q1 2024

May 09, 2024
BUY
$11.7 - $14.98 $17,667 - $22,619
1,510 Added 0.5%
305,426 $3.79 Million
Q4 2023

Feb 08, 2024
SELL
$13.09 - $14.98 $38,419 - $43,966
-2,935 Reduced 0.96%
303,916 $4.25 Million
Q3 2023

Nov 09, 2023
SELL
$12.64 - $14.99 $685,606 - $813,072
-54,241 Reduced 15.02%
306,851 $4.53 Million
Q2 2023

Aug 08, 2023
BUY
$9.85 - $13.17 $193,769 - $259,080
19,672 Added 5.76%
361,092 $4.67 Million
Q1 2023

May 11, 2023
BUY
$9.44 - $11.88 $175,499 - $220,861
18,591 Added 5.76%
341,420 $3.35 Million
Q4 2022

Feb 14, 2023
BUY
$10.27 - $13.29 $38,430 - $49,731
3,742 Added 1.17%
322,829 $3.44 Million
Q3 2022

Nov 10, 2022
BUY
$9.93 - $17.44 $95,943 - $168,505
9,662 Added 3.12%
319,087 $3.33 Million
Q2 2022

Aug 11, 2022
BUY
$7.45 - $12.83 $1.46 Million - $2.51 Million
195,318 Added 171.17%
309,425 $3.9 Million
Q1 2022

May 12, 2022
SELL
$9.75 - $14.44 $13,143 - $19,465
-1,348 Reduced 1.17%
114,107 $1.24 Million
Q4 2021

Feb 10, 2022
BUY
$13.17 - $20.94 $1,356 - $2,156
103 Added 0.09%
115,455 $1.62 Million
Q3 2021

Nov 12, 2021
BUY
$9.16 - $19.83 $38,875 - $84,158
4,244 Added 3.82%
115,352 $2.22 Million
Q2 2021

Aug 05, 2021
SELL
$7.25 - $10.99 $124,141 - $188,181
-17,123 Reduced 13.35%
111,108 $1.09 Million
Q1 2021

May 06, 2021
SELL
$4.57 - $11.18 $35,088 - $85,840
-7,678 Reduced 5.65%
128,231 $1.26 Million
Q4 2020

Feb 10, 2021
BUY
$3.73 - $5.6 $46,438 - $69,720
12,450 Added 10.08%
135,909 $605,000
Q3 2020

Nov 12, 2020
SELL
$4.32 - $11.7 $36,607 - $99,145
-8,474 Reduced 6.42%
123,459 $533,000
Q2 2020

Aug 13, 2020
BUY
$2.94 - $9.1 $88,593 - $274,219
30,134 Added 29.6%
131,933 $1.17 Million
Q1 2020

May 06, 2020
SELL
$2.27 - $6.2 $61 - $167
-27 Reduced 0.03%
101,799 $359,000
Q4 2019

Feb 05, 2020
BUY
$3.46 - $6.93 $21,119 - $42,300
6,104 Added 6.38%
101,826 $582,000
Q3 2019

Oct 23, 2019
BUY
$2.69 - $4.85 $26,012 - $46,899
9,670 Added 11.24%
95,722 $342,000
Q2 2019

Aug 14, 2019
BUY
$3.65 - $7.89 $10,814 - $23,378
2,963 Added 3.57%
86,052 $343,000
Q1 2019

May 01, 2019
SELL
$7.08 - $12.09 $9,388 - $16,031
-1,326 Reduced 1.57%
83,089 $607,000
Q4 2018

Jan 31, 2019
BUY
$8.14 - $13.28 $222,099 - $362,344
27,285 Added 47.76%
84,415 $772,000
Q3 2018

Nov 07, 2018
SELL
$11.85 - $16.0 $42,363 - $57,200
-3,575 Reduced 5.89%
57,130 $708,000
Q2 2018

Aug 06, 2018
SELL
$15.15 - $20.75 $7,211 - $9,877
-476 Reduced 0.78%
60,705 $926,000
Q1 2018

May 02, 2018
SELL
$14.65 - $19.9 $21,608 - $29,352
-1,475 Reduced 2.35%
61,181 $1.21 Million
Q4 2017

Feb 09, 2018
SELL
$17.3 - $24.08 $138,694 - $193,049
-8,017 Reduced 11.34%
62,656 $1.17 Million
Q3 2017

Nov 06, 2017
BUY
$15.2 - $21.5 $1.07 Million - $1.52 Million
70,673
70,673 $1.52 Million

Others Institutions Holding DVAX

# of Institutions
276
Shares Held
130M
Call Options Held
451K
Put Options Held
203K
View Full List

About DYNAVAX TECHNOLOGIES CORP

DVAX Quotes by TradingView
  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.63B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email